Simplify Asset Management Inc. Has $8.52 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Simplify Asset Management Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 67.4% in the third quarter, HoldingsChannel.com reports. The firm owned 13,770 shares of the medical research company’s stock after purchasing an additional 5,546 shares during the period. Thermo Fisher Scientific comprises about 0.4% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 25th largest holding. Simplify Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $8,518,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth $32,000. M&G Plc purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $90,951,000. Nicolet Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Nicolet Advisory Services LLC now owns 2,230 shares of the medical research company’s stock valued at $1,314,000 after acquiring an additional 88 shares during the last quarter. Cooper Haims Advisors LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth $202,000. Finally, Spirepoint Private Client LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $5,409,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock worth $20,651,865 in the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $19.03 during trading hours on Friday, hitting $513.99. 978,067 shares of the company’s stock traded hands, compared to its average volume of 1,460,813. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm’s 50-day moving average is $588.39 and its 200-day moving average is $582.69. The company has a market capitalization of $196.60 billion, a PE ratio of 32.68, a PEG ratio of 3.58 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52-week low of $464.17 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter last year, the firm posted $5.69 earnings per share. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Analyst Ratings Changes

Several brokerages recently weighed in on TMO. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Sanford C. Bernstein lowered their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research report on Thursday, October 24th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Finally, TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.